The University of Southampton
University of Southampton Institutional Repository

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors

Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
The increasing epidemic of obesity worldwide is linked to serious health effects, including increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). NAFLD is the liver manifestation of the metabolic syndrome and includes the spectrum of liver steatosis (known as nonalcoholic fatty liver) and steatohepatitis (known as nonalcoholic steatohepatitis), which can evolve into progressive liver fibrosis and eventually cause cirrhosis. Although NAFLD is becoming the number one cause of chronic liver diseases, it is part of a systemic disease that affects many other parts of the body, including adipose tissue, pancreatic β-cells and the cardiovascular system. The pathomechanism of NAFLD is multifactorial across a spectrum of metabolic derangements and changes in the host microbiome that trigger low-grade inflammation in the liver and other organs. Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear regulatory factors that provide fine tuning for key elements of glucose and fat metabolism and regulate inflammatory cell activation and fibrotic processes. This Review summarizes and discusses the current literature on NAFLD as the liver manifestation of the systemic metabolic syndrome and focuses on the role of PPARs in the pathomechanisms as well as in the potential targeting of disease.

1759-5045
24-39
Francque, Sven
9bbe5464-7b66-451f-8709-531ff3366828
Szabo, Gyongyi
9e161203-2da8-49b5-a2ff-b977c74704e9
Abdelmalek, Manal F.
30b694f2-ac41-4733-ad4b-ed77bf0b561b
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Cusi, Kenneth
5891f792-b89a-48fc-95fa-6766d28c1fa9
Dufour, Jean-François
ed6dfb64-1148-4219-a83a-cb3c96f5549c
Roden, Michael
0a2a54cf-cc07-48ce-b862-0cb822cf52f3
Sacks, Frank
02ddf34d-31ba-45f2-9be7-a286acecdd5d
Tacke, Frank
7320558d-2eab-46a7-a181-e2aa388dc810
Francque, Sven
9bbe5464-7b66-451f-8709-531ff3366828
Szabo, Gyongyi
9e161203-2da8-49b5-a2ff-b977c74704e9
Abdelmalek, Manal F.
30b694f2-ac41-4733-ad4b-ed77bf0b561b
Byrne, Christopher
1370b997-cead-4229-83a7-53301ed2a43c
Cusi, Kenneth
5891f792-b89a-48fc-95fa-6766d28c1fa9
Dufour, Jean-François
ed6dfb64-1148-4219-a83a-cb3c96f5549c
Roden, Michael
0a2a54cf-cc07-48ce-b862-0cb822cf52f3
Sacks, Frank
02ddf34d-31ba-45f2-9be7-a286acecdd5d
Tacke, Frank
7320558d-2eab-46a7-a181-e2aa388dc810

Francque, Sven, Szabo, Gyongyi, Abdelmalek, Manal F., Byrne, Christopher, Cusi, Kenneth, Dufour, Jean-François, Roden, Michael, Sacks, Frank and Tacke, Frank (2021) Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. Nature Reviews Gastroenterology & Hepatology, 18 (1), 24-39. (doi:10.1038/s41575-020-00366-5).

Record type: Review

Abstract

The increasing epidemic of obesity worldwide is linked to serious health effects, including increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic fatty liver disease (NAFLD). NAFLD is the liver manifestation of the metabolic syndrome and includes the spectrum of liver steatosis (known as nonalcoholic fatty liver) and steatohepatitis (known as nonalcoholic steatohepatitis), which can evolve into progressive liver fibrosis and eventually cause cirrhosis. Although NAFLD is becoming the number one cause of chronic liver diseases, it is part of a systemic disease that affects many other parts of the body, including adipose tissue, pancreatic β-cells and the cardiovascular system. The pathomechanism of NAFLD is multifactorial across a spectrum of metabolic derangements and changes in the host microbiome that trigger low-grade inflammation in the liver and other organs. Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear regulatory factors that provide fine tuning for key elements of glucose and fat metabolism and regulate inflammatory cell activation and fibrotic processes. This Review summarizes and discusses the current literature on NAFLD as the liver manifestation of the systemic metabolic syndrome and focuses on the role of PPARs in the pathomechanisms as well as in the potential targeting of disease.

Text
NRGH accepted manuscript - Accepted Manuscript
Download (455kB)
Image
Fig 1 NRGH-19-249V1A - Accepted Manuscript
Download (148kB)
Image
Fig 2 NRGH-19-249V1A - Accepted Manuscript
Download (1MB)
Image
Fig 3_Nat Rev Gast Hep_2019 - Accepted Manuscript
Download (44kB)

More information

Accepted/In Press date: 2 September 2020
e-pub ahead of print date: 22 October 2020
Published date: 1 January 2021
Additional Information: Funding Information: S.F. has a senior clinical research mandate from the Fund for Scientific Research (FWO) Flanders (1802154N) and has acted as advisor and/or lecturer for Roche, Gilead, Abbvie, Bayer, BMS, MSD, Janssen, Actelion, Astellas, Genfit, Inventiva, Intercept, Genentech and Galmed. G.S. has received research support from NIAAA (NIH), Gilead, Intercept, Allergan, Genfit, Novartis, SignaBlock, Shire, the University of Florida, BMS, Genentech, Takeda, and Vertex. She is a consultant/advisory board member for Allergan, Arrow Diagnostics, Pandion Therapeutics, Glympse Bio, Quest Diagnostic, Surrozen, Innovate Biopharmaceuticals, Alnylam, Zomagen, Novartis, Durect, Generon and Terrafirma. She is an author for UptoDate, editor for the American Association for the Study of Liver Diseases and Editor-in-Chief of Hepatology Communications. M.F.A. is supported by the National Institute of Health (NIH)/NIDDK Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN, U01DK061713, PI: A.M. Diehl) and is an advisor/consultant for Bristol Myers Squibb, NGM Pharma, Inventiva, Taiwan J, Immuron, Prometheus, and Novo-Nordisk. Her institution receives funding for research from NIH/NIDDK, Inventiva, Enyo, Enanta, Allergan, Novartis, Genfit, Intercept, BMS, NGM Parma, Gilead, Conatus, Durect, Poxel, Madrigal, Celgene, Galactin, Galmed, Novo-Nordisk, Taiwan J, Prometheus, TARGET NASH, and Progenity. She serves on speaker’s bureau for Simply Speaking NASH, iHEP NASH, PRIME NASH Programming, Clinical Care Options, and Alexion. C.D.B. is supported by the National Institute for Health Research (NIHR) through the NIHR Southampton Biomedical Research Centre. He is a consultant for Inventiva. K.C. has received research support for the University of Florida as principal investigator from the NIH, Cirius, Echosens, Inventiva, Novartis, Novo Nordisk, Poxel, TARGET NASH and Zydus. He is a consultant for Allergan, Astra-Zeneca, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Genentech, Gilead, Janssen, Merck, Pfizer, Poxel, Prosciento, Novo Nordisk, Sanofi-Aventis, and TARGET NASH. J.-F.D. is a consultant/advisory board member for Abbvie, Allergan, Bayer, Bristol-Myers Squibb, Falk, Genfit, Genkyotex, Gilead Science, HepaRegenix, Intercept Pharma, Lilly, Merck, and Novartis. He serves as an investigator of studies supported by Abbvie, Bayer, BMS, Falk, Genfit, Gilead Science, Intercept, Inventiva, Lilly, Merck, and Novartis. M.R. has received research support from the Ministry of Culture and Science of the State of North Rhine-Westphalia and the German Federal Ministry of Health, grants from the European Fonds for Regional Development (EFRE-0400191), German Research Foundation (DFG, SFB 1116/2) and the Schmutzler Stiftung, serves as investigator of studies supported by Boehringer-Ingelheim Pharma, Nutricia/Danone, and Sanofi, and was advisor/consultant for Bristol-Myers Squibb, Eli Lilly, Gilead, Intercept Pharma, Novo Nordisk, Novartis, Poxel, Prosciento, Sanofi, Servier, and TARGET NASH. F.S. is a consultant to Pfizer, AstraZeneca, and Abbvie. F.T. has received research funding at Charité University Medicine Berlin from Allergan, Bristol-Myers Squibb, Galapagos, and Inventiva. He is a consultant for Allergan, Bayer, Boehringer Ingelheim, Galapagos, Galmed, Intercept, Inventiva, and Pfizer. Publisher Copyright: © 2020, Springer Nature Limited.

Identifiers

Local EPrints ID: 443815
URI: http://eprints.soton.ac.uk/id/eprint/443815
ISSN: 1759-5045
PURE UUID: 74f84301-568e-4613-8bea-208ed3056457
ORCID for Christopher Byrne: ORCID iD orcid.org/0000-0001-6322-7753

Catalogue record

Date deposited: 14 Sep 2020 16:31
Last modified: 17 Mar 2024 05:53

Export record

Altmetrics

Contributors

Author: Sven Francque
Author: Gyongyi Szabo
Author: Manal F. Abdelmalek
Author: Kenneth Cusi
Author: Jean-François Dufour
Author: Michael Roden
Author: Frank Sacks
Author: Frank Tacke

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×